Actively Recruiting
Phase 1/2 Study of IDP-023 Alone and With Antibody Therapies in Advanced Blood Cancers
Led by Indapta Therapeutics, INC. · Updated on 2025-06-03
128
Participants Needed
12
Research Sites
208 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating IDP-023, an off-the-shelf cell therapy made of natural killer (NK) cells, in patients with advanced blood cancers including relapsed or refractory multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL). This open-label, first-in-human Phase 1/2 study aims to assess the safety, tolerability, and early anti-cancer effects of IDP-023 given alone or combined with immune therapies such as interleukin-2, isatuximab, daratumumab, or rituximab. The study is sponsored by Indapta Therapeutics, INC.
CONDITIONS
Brief Title
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Who Can Participate
Eligibility Criteria
You may qualify if you...
- For multiple myeloma patients: diagnosed with multiple myeloma requiring systemic therapy and relapsed or refractory after at least 3 prior treatments
- For non-Hodgkin's lymphoma patients: relapsed or refractory disease after at least 2 lines of chemotherapy
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Life expectancy greater than 12 weeks as assessed by the investigator
You will not qualify if you...
- Impaired heart function or history of significant heart disease
- Infection with HIV, active hepatitis B, or hepatitis C
- Active COVID-19 infection
- Untreated central nervous system, epidural tumor metastasis, or brain metastasis
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 1 year in Phase 1 and up to 2 years in Phase 2
Participants receive IDP-023 as a single agent or in combination with antibody therapies to treat advanced multiple myeloma or non-Hodgkin's lymphoma.
Multiple dosing visits according to assigned regimen
Duration - Up to 2 years
Participants are monitored for safety, tolerability, and anti-tumor activity after treatment.
Regular follow-up visits during the monitoring period
Trial Site Locations
Total: 12 locations
1
Valkyrie Clinical Trials
Los Angeles, California, United States, 90670
Actively Recruiting
2
Florida Cancer Specialists and Research Institute - Lake Mary Cancer Center
Lake Mary, Florida, United States, 32746
Withdrawn
3
Emory University Hospital
Atlanta, Georgia, United States, 30322
Actively Recruiting
4
University of Minnesota
Minneapolis, Minnesota, United States, 55455
Actively Recruiting
5
NYP/Weill Cornell Medical Center
New York, New York, United States, 10065
Withdrawn
6
Atrium Health Wake Forest Baptist
Winston-Salem, North Carolina, United States, 27157
Actively Recruiting
7
University Hospitals Cleveland
Cleveland, Ohio, United States, 44106
Actively Recruiting
8
Providence Cancer Institute Franz Clinic
Portland, Oregon, United States, 97213
Withdrawn
9
Rhode Island Hospital
Providence, Rhode Island, United States, 02903
Actively Recruiting
10
SCRI Oncology Partners
Nashville, Tennessee, United States, 37203
Actively Recruiting
11
University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
12
NEXT Oncology Virginia
Fairfax, Virginia, United States, 22031
Actively Recruiting
Research Team
I
Indapta Therapeutics, Inc.
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
6
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here